Synexus, the world’s leading investigative site network for clinical trials, has acquired Optimal Research, LLC., a subsidiary of Accelovance that operates dedicated research sites offering clinical research and specialist laboratory services.

The transaction expands Synexus’ global capabilities to serve biopharmaceutical and contract research organization customers, adding Optimal’s six dedicated research sites (DRSs) across the United States. The addition of the DRSs broadens Synexus’ therapeutic reach into vaccines/infectious diseases and extends its capabilities in general medicine, men’s and women’s health, and medical devices.

In addition, Synexus gains expertise in high-value laboratory offerings, including peripheral blood mononuclear cells (PBMC) isolation through on-site PBMC processing labs, which meet a growing industry need for higher recovery and viability for time-sensitive lab specimens.

“By deepening our scope and adding the expertise of our new colleagues from Optimal Research, we are magnifying Synexus’ unmatched capability to find the right patient for the right trial at the right time,” said Christophe Berthoux, chief executive officer of Synexus. “Our clients will experience clear benefits from our expanded dedicated research site offerings and in multiple therapeutic areas, including in vaccines.”

Stephen Bart, M.D., president and chief medical officer of Optimal Research, will join the Synexus leadership team and oversee vaccine services capabilities. Optimal’s dedicated research sites have specialized in clinical trials for vaccine and infectious disease products for more than a decade, with more than 300 studies conducted in recent years in areas such as Ebola, filovirus, Zika and respiratory syncytial virus (RSV).